Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,474.09 -1.00 (-0.02%) Dow
39,104.05 -65.47 (-0.17%) Nasdaq
17,890.18 +10.88 (+0.06%) Bitcoin USD
61,785.53 -1,233.72 (-1.96%) CMC Crypto 200
1,310.36 -34.15 (-2.54%)
INDV Jul 2024 17.500 call
- PR Newswire
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest
Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a modeling study in Frontiers in Psychiatry that predicts OPVEE (nalmefene) nasal spray (2.7 mg nalmefene, equivalent to 3 mg of nalmefene hydrochloride) resulted in larger reductions in the incidence of simulated cardiac arrest following overdose from high doses of potent synthetic opioids, compared to a 4 mg dose of IN naloxone.
- PR Newswire
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
Indivior PLC (LSE/Nasdaq: INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with Opioid Use Disorder (OUD) (NCT06384157). The purpose of this proof-of-concept study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe OUD who
- Simply Wall St.
With 59% ownership, Indivior PLC (LON:INDV) boasts of strong institutional backing
Key Insights Institutions' substantial holdings in Indivior implies that they have significant influence over the...
